Exploratory Analysis of Liraglutide Effects on Obstructive Sleep Apnea and Health‐Related Quality of Life in Individuals With Obesity and COPD : A Secondary Analysis of a Randomised Controlled Trial
Clinical Obesity · 2026-04 · 16 (2)
DOI: 10.1111/cob.70079 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Obesity, online erschienen am 23.03.2026. Verfasst von Sofie Krogh Wolsing und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University Hospital of Southern Denmark, Vejle, Denmark. Hauptthemen laut MEDLINE: Liraglutide, Obesity, Pulmonary Disease, Chronic Obstructive, Quality of Life. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk, Karola Jørgensens Forskningsfond, Research Council of Hospital South West Jutland, University hospital of Southern Denmark.
Themen: COPD
Abstract (Originalsprache)
Obstructive sleep apnea (OSA) is associated with chronic obstructive pulmonary disease (COPD) and obesity, and all three are linked to reduced health‐related quality of life (HRQoL). Coexistence of OSA and COPD increases morbidity and mortality compared to each condition alone. Liraglutide, a glucagon‐like peptide 1 receptor agonist, may influence respiratory and HRQoL outcomes. In this secondary exploratory analysis of a randomised controlled trial including individuals with overweight or obesity and COPD, we evaluated effects of liraglutide on OSA prevalence and severity, daytime sleepiness (Epworth Sleepiness Scale, ESS), and HRQoL (Short Form‐36 version 2, SF‐36v2). In a double‐blinded randomised controlled trial, 40 participants with overweight or obesity and COPD from two outpatient clinics were randomised to liraglutide (3.0 mg, subcutaneous) or placebo for 40 weeks. Cardiorespiratory monitoring, SF‐36v2 and ESS questionnaires were conducted at baseline and end of treatment. OSA was diagnosed in 84% of participants (70% in the liraglutide group and 85% in the placebo group). Compared to placebo, liraglutide significantly reduced OSA severity, with mean baseline‐adjusted differences of −9.87 events/h (β 95% CI −19.5; −0.247, p = 0.044) in Apnea–Hypopnea Index and −10.16 events/h (β 95% CI −19.29; −1.03, p = 0.029) in Oxygen Desaturation Index. ESS scores did not change significantly. Significant improvements were observed in the SF‐36v2 subdomains General Health Perception and Role Physical. OSA is common among individuals with overweight or obesity and COPD. Forty weeks of liraglutide treatment were associated with reduced OSA severity and improvements in selected HRQoL domains in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University Hospital of Southern Denmark, Vejle, Denmark.
- Department of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.
- Department of Medicine, Regional Hospital Horsens, Horsens, Denmark.
- Department of Medicine, University Hospital of Southern Denmark, Esbjerg, Denmark.
- Steno Diabetes Center, Odense, Denmark.
- Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark.
ORCID-Profile: Sofie Krogh Wolsing, Ole Hilberg
Förderung
- Novo Nordisk
- Karola Jørgensens Forskningsfond
- Research Council of Hospital South West Jutland, University hospital of Southern Denmark
- Region Syddanmark
Zitieren
APA
Wolsing, S. K., Dogan, A. D. A., Juhl, C. B., Hess, S., Jensen, T. T., Bladbjerg, E. M., & Hilberg, O. (2026). Exploratory Analysis of Liraglutide Effects on Obstructive Sleep Apnea and Health‐Related Quality of Life in Individuals With Obesity and COPD : A Secondary Analysis of a Randomised Controlled Trial. Clinical Obesity, 16(2). https://doi.org/10.1111/cob.70079
Vancouver
Wolsing SK, Dogan ADA, Juhl CB, Hess S, Jensen TT, Bladbjerg EM, et al. Exploratory Analysis of Liraglutide Effects on Obstructive Sleep Apnea and Health‐Related Quality of Life in Individuals With Obesity and COPD : A Secondary Analysis of a Randomised Controlled Trial. Clinical Obesity. 2026;16(2). doi:10.1111/cob.70079
BibTeX
@article{Wolsing2026,
author = {Wolsing, Sofie Krogh and Dogan, Ayse Dudu Altintas and Juhl, Claus Bogh and Hess, Søren and Jensen, Torben Tranborg and Bladbjerg, Else-Marie and Hilberg, Ole},
title = {Exploratory Analysis of Liraglutide Effects on Obstructive Sleep Apnea and Health‐Related Quality of Life in Individuals With Obesity and COPD : A Secondary Analysis of a Randomised Controlled Trial},
journal = {Clinical Obesity},
year = {2026},
volume = {16},
number = {2},
doi = {10.1111/cob.70079}
}
EUVIMED